Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Windtree Therapeutics Inc (NQ: WINT )

3.900 +0.280 (+7.73%)
Streaming Delayed Price Updated: 3:58 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,219
Open 3.700
Bid (Size) 3.800 (1)
Ask (Size) 4.000 (1)
Prev. Close 3.620
Today's Range 3.700 - 3.990
52wk Range 0.2654 - 6.110
Shares Outstanding 5,148,219
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news! 
Via InvestorPlace
(WINT) - Analyzing Windtree Therapeutics's Short Interest
Via Benzinga

Performance

YTD
+458.66%
+458.66%
1 Month
-24.35%
-24.35%
3 Month
+1127.96%
+1127.96%
6 Month
+319.35%
+319.35%
1 Year
+200.00%
+200.00%

More News

Read More
Why Windtree Therapeutics (WINT) Stock Is Getting Hammered
Via Benzinga
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
WINT Stock Earnings: Windtree Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Windtree Therapeutics – This Biotech Inks License Deal For Lead Candidate
Via Benzinga
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Windtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
Via Benzinga
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Windtree Therapeutics Announces Reduction In Arrhythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
Via Benzinga
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
Via ACCESSWIRE
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected mid-2024
Via Benzinga
Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
Via ACCESSWIRE
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.